Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2

Scott R. Plotkin, Vanessa L. Merker, Chris Halpin, Dominique Jennings, Michael J. McKenna, Gordon J. Harris, Fred G. Barker

Otology & Neurotology · 2012 · 253 citations · 25 references

DOIFull text

Open access

Concepts

TL;DR

Early studies suggest that bevacizumab can shrink vestibular schwannomas and improve hearing in patients with neurofibromatosis type 2. The study reports extended follow‑up of bevacizumab treatment in a larger cohort of NF2 patients with progressive vestibular schwannomas. In a retrospective cohort of 31 NF2 patients (median age 26 yr), bevacizumab was given for a median of 14 months (range 6–41 mo), with a pre‑treatment tumor growth rate of 64 % per year and 47 patient‑years of follow‑up. Bevacizumab produced hearing improvement in 57 % and radiographic tumor shrinkage in 55 % of patients, with median response at 3 months; 90 % maintained hearing and 88 % had stable or reduced tumor size at 1 year, and the treatment was well tolerated.

Abstract

Early studies suggest that bevacizumab treatment can result in tumor shrinkage and hearing improvement for some patients with neurofibromatosis type 2 (NF2). The aim of this study was to report extended follow-up in a larger cohort of similarly treated patients.Retrospective study.Tertiary referral centerThirty-one consecutive NF2 patients who received bevacizumab for progressive vestibular schwannomas.Hearing improvement, defined as an improvement in word recognition score above the 95% critical difference compared with baseline, and radiographic response, defined as a 20% or greater decrease in tumor volume compared with baseline.The median age was 26 years (range, 12-73 yr). The median volumetric tumor growth rate before treatment was 64% per year. At the time of analysis, the median duration of treatment was 14 months (range, 6-41 mo) with a total of 47 patient-years of follow-up. A hearing response occurred in 57% (13/23) of evaluable patients and a radiographic response in 55% (17/31) of target vestibular schwannomas. The median time to response was 3 months for both end points. The only clinical or radiographic feature at baseline that correlated with change in tumor volume at 3 months was the mean apparent diffusion coefficient value, a radiologic marker of edema (p = 0.036). Ninety percent of patients had stable or improved hearing after 1 year of treatment and 61% at 3 years; 88% of patients had stable or decreased tumor size after 1 year of treatment and 54% at 3 years. Overall, treatment was well tolerated.Bevacizumab treatment was followed by hearing improvement and tumor shrinkage in more than 50% of progressive vestibular schwannomas in NF2 patients. Stable or improved hearing was retained in the majority of patients.

References

25